3a,4-Dihydropyrazolo[1,5 a]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase β Inhibitors

ACS Medicinal Chemistry Letters

Volumn 4, Issue 2, 2013, Pages 230-234

  Yu, Hongyi ^a   Moore, Michael L ^a   Erhard, Karl ^a   Hardwicke, Mary Ann ^b   Lin, Hong ^a   Luengo, Juan I ^a   McSurdy Freed, Jeanelle ^c   Plant, Ramona ^b   Qu, Junya ^a   Raha, Kaushik ^d   Rominger, Cynthia M ^b   Schaber, Michael D ^e   Spengler, Michael D ^c   Rivero, Ralph A ^a  

^a Cancer Metabolism Chemistry   (United States)

^b Cancer Metabolism Biology   (United States)

^c Cancer Metabolism DMPK   (United States)

^d Platform Technology and Science   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

phosphatidylinositol 3 kinase; PI3K inhibitor; PTEN null; pyrazolopyrimidine; structure activity relationship

Indexed keywords

[3ALPAH,4]DIHYDROPYRAZOLO[1,5ALPHA]PYRIMIDINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE BETA INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; HAPLORHINI; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

EID: 84873981303     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300330m     Document Type: Article

References (25)

1. Fruman, D. A.; Meyers, R. E.; Cantley, L. C. Phosphoinositide Kinases Annu. Rev. Biochem. 1998, 67, 481-507
2. Rameh, L. E.; Cantley, L. C. The Role of Phosphoinositide 3-Kinase Lipid Products in Cell Function J. Biol. Chem. 1999, 274, 8347-8350
3. Aoki, M.; Schetter, C.; Himly, M.; Batista, O.; Chang, H. W.; Vogt, P. K. The Catalytic Subunit of Phosphoinositide 3-Kinase: Requirements for Oncogenicity J. Biol. Chem. 2000, 275, 6267-6275
4. Kang, S.; Bader, A. G.; Vogt, P. K. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 802-807
5. Vogt, P. K.; Kang, S.; Elsliger, M.-A.; Gymnopoulos, M. Cancer-specific mutations in phosphatidylinositol 3-kinase Trends Biochem. Sci. 2007, 32, 342-349
6. Engelman, J. A. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations Nat. Rev. Cancer 2009, 9, 550-562
7. Nuss, J. M.; Tsuhako, A. L.; Anand, N. K. Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol 3-Kinases Annu. Rep. Med. Chem. 2009, 44, 339-355
8. Höland, K.; Salm, F.; Arcaro, A. The Phosphoinositide 3-Kinase Signalling Pathway as a Therapeutic Target in Grade IV Brain Tumors Curr. Cancer Drug Targets 2011, 11, 894-918
9. Samuels, Y.; Ericson, K. Oncogenic PI3K and its role in cancer Curr. Opin. Oncol. 2006, 18, 77-82
10. Zhang, J.; Roberts, T. M.; Shivdasani, R. A. Targeting PI3K Signalling as a Therapeutic Approach for Colorectal Cancer Gastroenterology 2011, 141, 50-61
11. Jia, S.; Liu, Z.; Zhang, S.; Liu, P.; Zhang, L.; Lee, S. H.; Zhang, J.; Signoretti, S.; Loda, M.; Roberts, T. M.; Zhao, J. J. Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis Nature 2008, 454, 776-780
12. Wee, S.; Wiederschain, D.; Maira, S.-M.; Loo, A.; Miller, C.; deBeaumont, R.; Stegmeier, F.; Yao, Y.-M.; Lengauer, C. PTEN-deficient cancers depend on PI3KCB Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 13057-13062
13. Lee, S. H.; Poulogiannis, G.; Pyne, S.; Jia, S.; Zou, L.; Signoretti, S.; Loda, M.; Cantley, L. C.; Roberts, T. M. A constitutively activated form of the p110β isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 11002-11007
14. Hill, K. M.; Kalifa, S.; Das, J. R.; Bhatti, T.; Gay, M.; Williams, D.; Taliferro-Smith, L.; De Marzo, A. M. The Role of PI3-Kinase p110β in AKT Signalling, Cell Survival, and Proliferation in Human Prostate Cancer Cells Prostate 2010, 70, 755-764
15. Dbouk, H. A.; Backer, J. M. A beta version of life: p110β takes center stage Oncotarget 2010, 1, 729-733
16. Lin, H.; Erhard, K.; Hardwicke, M. A.; Luengo, J. I.; Mack, J. F.; McSurdy-Freed, J.; Plant, R.; Raha, K.; Rominger, C. M.; Sanchez, R.; Schaber, M. D.; Schulz, M.; Spengler, M. D.; Tedesco, R.; Xie, R.; Zeng, J. J.; Rivero, R. A. Synthesis and structure-activity relationships of imidazo[1,2a]pyrimidin- 5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol-3- kinase inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 2230-2234
17. Sanchez, R.; Erhard, K.; Hardwicke, M. A.; Lin, H.; McSurdy-Freed, J.; Plant, R.; Raha, K.; Rominger, C. M.; Schaber, M. D.; Spengler, M. D.; Moore, M. L.; Yu, H.; Luengo, J. I.; Tedesco, R.; Rivero, R. A. Synthesis and structure activity relationships of 1,2,4-triazolo[1,5a]pyrimidin-7(3H)-ones as a novel series of potent beta isoform selective phosphatidylinositol 3-kinase inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 3198-3202
18. O'Brien, D. E.; Robins, R. K. Xanthine Oxidase Inhibitors. U.S. Patent 3,907,799, September 23, 1975.
19. Guzi, T. J.; Paruch, K.; Dwyer, M. P. Novel Pyrazolopyrimidines as Cyclin Dependent Kinase Inhibitors. U.S. 2006/0041131, February 23, 2006.
20. Hunt, P.; Porter, D.; Press, N. J.; Spanka, C.; Watson, S. J. 5-Sulfanylmethyl-pyrazolo[1,5a]pyrimidin-7-ol Derivatives as CXCR2 Antagonists. WO 2008/062026, May 29, 2008.
21. Lin, L. S.; Hagmann, W. K.; Kumar, S.; Yin, W. Substituted Amides. WO 2004/058145, July 15, 2004.
22. Gray, A.; Olsson, H.; Batty, I. H.; Priganica, L.; Downes, C. P. Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts Anal. Biochem. 2003, 313, 234-245
23. Ikawa, T.; Barder, T. E.; Biscoe, M. R.; Buchwald, S. L. Pd-Catalyzed Amidations of Aryl Chlorides Using Monodentate Biaryl Phosphine Ligands: A Kinetic, Computational and Synthetic Investigation J. Am. Chem. Soc. 2007, 129, 13001-13007
24. Lin, H.; Schulz, M. J.; Xie, R.; Luengo, J. I.; Squire, M. D.; Tedesco, R.; Qu, J.; Erhard, K.; Mack, J. F.; Raha, K.; Plant, R.; Rominger, C. M.; Ariazi, J. L.; Sherk, C. S.; Schaber, M. D.; McSurdy-Freed, J.; Spengler, M. D.; Davis, C. B.; Hardwicke, M. A.; Rivero, R. A. Rational design, synthesis and SAR of a novel thiazolopyrimidinone series of selective PI3Kβinhibitors ACS Med. Chem. Lett. 2012, 3, 524-529
25. Smith, D. A.; Di, L.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nature Rev. Drug Discovery 2010, 9, 929-939